Nuvalent, Inc. (NUVL) Research

Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.

Market snapshot

Symbol
NUVL
Price
$123.43
Day change
+0.06%
Market cap
$9.1B
P/E ratio
-21.57x
52-week range
71.13-123.62
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$132.74

Recent news

  • Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal

    GSK's record $10.6 billion deal for U.S. company Nuvalent will accelerate the British drugmaker's rebuild of its cancer drug business as it seeks ​to fend off competition from bigger rivals AstraZeneca and Roche.

  • JM Smucker, Nuvalent, FuelCell Energy And Other Big Stocks Moving Higher On Tuesday

    U.S. stocks were higher, with the Dow Jones index gaining over 300 points on Tuesday.

  • 5 Things to Know Before the Stock Market Opens

    Stock futures are pointing to a higher open Tuesday as the market looks to extend its recovery from last week's losses; President Trump said last night that the U.S. and Iran are close to a "very, very good deal;" OpenAI has confidentially filed with the SEC for an IPO, but said in a statement it doesn't have a timeline for going public; Nuvalent shares are soaring after the drugmaker agreed to be acquired by British pharmaceutical giant GSK; and Vail Resorts shares are down after the company cut its outlook for the second time this year. Here's what you need to know today.

Peer companies

  • Abivax S.A. (ABVX)
  • Arrowhead Pharmaceuticals, Inc. (ARWR)
  • Axsome Therapeutics, Inc. (AXSM)
  • CRISPR Therapeutics AG (CRSP)
  • Cytokinetics, Incorporated (CYTK)
  • Jazz Pharmaceuticals plc (JAZZ)
  • Merus N.V. (MRUS)
  • Metsera, Inc. (MTSR)

Recent insider activity

  • Flynn James E — A-Award (3444 shares) on 2026-06-16
  • Wheeler Cameron — A-Award (3444 shares) on 2026-06-16
  • Srivastava Sapna — A-Award (3444 shares) on 2026-06-16
  • Squarer Ron — A-Award (3444 shares) on 2026-06-16
  • Protopapas Anna — A-Award (3444 shares) on 2026-06-16

Open Nuvalent, Inc. (NUVL) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.